Pro- and anticarcinogenic mechanisms of piceatannol are activated dose dependently in MCF-7 breast cancer cells
Nha T.P. Vo(University of Vienna), Afschin Soleiman(Medical University of Vienna), Georg Krupitza(Medical University of Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Sibylle Madlener(Comprehensive Cancer Center Vienna), Caroline Vonach(Medical University of Vienna), Benedikt Giessrigl(Medical University of Vienna), Thomas Szekeres(Medical University of Vienna), Irene Herbacek(Comprehensive Cancer Center Vienna), Manuela Gridling(Austrian Academy of Sciences), Philipp Saiko(Ludwig Boltzmann Institute Applied Diagnostics), Monika Fritzer‐Szekeres(Vienna General Hospital), Nicole Stark(Medical University of Vienna), Walter Jäger, Sabine Bauer(Medical University of Vienna), Michael Grusch(Comprehensive Cancer Center Vienna), Paul Probst(Medical University of Vienna)
Cited by 28
Related Papers
What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol
|PLoS ONE|2011|437
Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice
|Science|2018|422
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
|Annals of Oncology|2013|403
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
|Nature Medicine|2022|395
Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure–activity relationship
|Biochemical Pharmacology|2005|303